PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Celo is an app-based insurance provider designed to provide cheaper quotes, faster claims, and a pleasant user experience. We plan to offer insurance cover for motor vehicles, travel, health, and more. Like Monzo and Starling who are disrupting banking, Celo plans to disrupt the insurance industry.
days to go:
Expired
investment:
£142,840
AgeWage is a pension scoring system that provides customized information to the customers. By bringing together your pension pots, AgeWage scores each of the pension pot out of 100 and tells you how well they have worked for you. The scoring system offers information that helps the customer make decisions on how to consolidate pots, reinvest their money and most importantly, how to get their money back. The company has signed an MoU with Royal London to enter into B2B arrangements. It was also chosen for the Direct Support Innovate programme with the FCA. AgeWage has been voted the best new idea in the BGL partnership awards(2018). With its proceeds, the company is planning to invest in digital development, marketing the application to the general public and other organizations. Also, it is trying to build out the infrastructure to support the development of the product with third parties such as Annuity Providers, IFAs, and Drawdown Providers.
days to go:
Expired
investment:
£317,760
An innovation event that displays the greatest in medical healthcare technologies within exhibitions, conferences and workshops. GIANT Health has over 2000 delegates registered, with 235 speakers and 33 exhibitors whilst being sponsored by 8 global companies. Current revenue streams consist of event ticket sales, partnership packages, stage demos, etc. Events are held across Europe, with international expansion in the next phase.
days to go:
Expired
investment:
£62,770
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go:
Expired
investment:
£451,506
Pedal Me uses high-tech cargo bikes, trailers and trained riders to provide delivery & taxi services when needed. The company offers a solution that will out-perform motors in car-centric cities as bike-friendly measures like bike lanes are introduced. As of now, the company has 32 bikes and 45 staff in total. It has witnessed a strong MoM growth (19% on avg). The trips provided by Pedal Me has negligible carbon footprint in comparison with vans, taxis or electric vehicles. With the funds, the company will improve the technology, maintain speed with demand, develop the staff and balance the process.
days to go:
Expired
investment:
£421,330
Parcel2go based in Bolton, Greater Manchester is the UK’s leading parcel delivery comparison website, offering a surprisingly cheap alternative to the Post Office to consumers and small eBay sellers/businesses. Our website enables you to send anything, from a small packet to a large parcel, to destinations throughout the UK and internationally, and all for a surprisingly cheap price.
days to go:
Expired
investment:
£1,057,730
